A carregar...
Maintained Clinical Remission in Ankylosing Spondylitis Patients Switched from Reference Infliximab to Its Biosimilar: An 18-Month Comparative Open-Label Study
Background: Switching from reference infliximab (RI) to biosimilar infliximab (BI) had no detrimental effects on efficacy and safety. However, long-term follow-up data is missing. Objective: To evaluate patients with Ankylosing Spondylitis (AS) in clinical remission who were switching from RI to BI,...
Na minha lista:
| Publicado no: | J Clin Med |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6679061/ https://ncbi.nlm.nih.gov/pubmed/31269678 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8070956 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|